Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation

References

• Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407–419
   PubMed Web of Science ®Google Scholar
• Chauhan D, Chao T H, Catley L, Nicholson B, Velankar M, Hideshima T, et al. In vitro and in vivo proteasome activity profiles of bortezomib and a novel proteasome inhibitor NPI-0052. Blood 2005; 106: 3363 (abstract).
   Google Scholar
• Miller C P, Ban K, Ruiz S L, Neuteboom S T, Palladino M A, McConkey D, et al. The novel, orally active proteasome inhibitor, NPI-0052, induces apoptosis in leukemia lymphoma cell lines and patient specimens. Blood 2005; 106: 241 (abstract).
   Web of Science ®Google Scholar
• Suzuki E, Jazirehi A, Palladino M A, Bonavida B. Chemosensitization of drug and rituximab-resistant daudi B-NHL clones to drug-induced apoptosis by the proteasome inhibitor NPI-0052. Blood 2005; 106: 1521(abstract).
   Web of Science ®Google Scholar
• Demo S D, Kirk C J, Aujay M A, Buchholz T J, Dajee M, Ho M N, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007; 67: 6383–6391
   PubMed Web of Science ®Google Scholar
• Pahler J C, Ruiz S, Niemer I, Calvert L R, Andreeff M, Keating M, et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 2003; 9: 4570–4577
   PubMed Web of Science ®Google Scholar
• Chauhan D, Catley L, Velankar M, Letai A, Hideshima T, Podar K, et al. Requirement of caspase-8 versus caspase-9 during apoptosis in multiple myeloma cells induced by bortezomib or a novel proteasome inhibitor NPI-0052. Blood 2005; 106: 3378 (abstract).
   Google Scholar
• O'Connor O A, Moskowitz C, Wright J, MacGregor-Cortelli B, Straus D, Furst D, et al. Phase II clinical experience with the proteasome inhibitor PS-341 in patients with indolent lymphomas. Blood 2002; 100: 3063, (abstract)
   PubMed Web of Science ®Google Scholar
• Belch A, Kouroukis T, Crump M, Sehn L, Gascoyne R, Klasa R, et al. Phase II trial of bortezomib in mantle cell lymphoma. Blood 2004; 104: 608(abstract).
   Google Scholar
• Goy A, Younes A, McLaughlin P, Pro B, Romaguera J E, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein S H, Kahl B S, Epner E, Leonard J P, Stadtmauer E A, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. J Clin Oncol 2005; 23: 6563. (abstract)
   Web of Science ®Google Scholar
• O'Connor O A, Wright J, Moskowitz C, Straus D, Portlock C S, Hamlin P, et al. Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival among responding patients: results of a multicenter phase II experience. Ann Oncol 2005; 16: 99. (abstract)
   Google Scholar
• Strauss S, Maharaj L, Hoare S, Trehu E, Boral A, Schenkein D, et al. Bortezomib (Velcade) in patients with relapsed/refractory lymphoma: potential correlation of TNF-alpha response and in vitro sensitivity with clinical activity. Ann Oncol 2005; 16: 97. (abstract)
   Web of Science ®Google Scholar
• Dimopoulos M A, Anagnostopoulos A, Kyrtsonis M C, Castritis E, Bitsaktsis A, Pangalis G A. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005; 90: 1655–1658
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein S H, Kahl B S, Djulbegovic B, Robertson M J, Boral A, et al. Bortezomib in relapse or refractory mantle cell lymphoma (MCL): results of the PINNACLE study. J Clin Oncol 2006; 24: 7512. (ASCO Meeting abstract)
   Google Scholar
• Fisher R I, Bernstein S H, Kahl B S, Djulbegovic B, Robertson M J, de V S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867–4874
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN Clinical Practice Guidelines in oncology: non-Hodgkin's lymphomas (v3.2007). 2007
   Google Scholar
• Greco F A, Spigel D R, Barton J H, Farley C, Schreeder M T, Hermann R C, et al. Weekly bortezomib in the treatment of patients (pts) with previously treated multiple myeloma: a phase II trial of the Minnie Pearl cancer research network. J Clin Oncol 2006; 24: 7547. (ASCO Meeting abstract)
   Google Scholar
• Gerecitano J, Portlock C S, Noy A, Hamlin P, Moskowitz C, Straus D, et al. The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, inpatients with relapsed/refractory indolent B-cell lymphoproliferative disorders. Blood 2006; 108: 2759. (abstract)
   Google Scholar
• Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257–264
   PubMed Web of Science ®Google Scholar
• Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530–1534
   PubMed Web of Science ®Google Scholar
• Bartlett J B, Dredge K, Dalgleish A G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314–322
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar S V. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 2006; 42: 1612–1622
   PubMed Web of Science ®Google Scholar
• Marriott J B, Dredge K, Dalgleish A G. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents. Curr Drug Targets Immune Endocr Metab Disord 2003; 3: 181–186
   PubMedGoogle Scholar
• Richardson P G, Schlossman R L, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067
   PubMed Web of Science ®Google Scholar
• Davies F E, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon S P, Shima Y, Hideshima T, Podar K, Tai Y T, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950–1961
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, Raje N, Davies F E, Tai Y T, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943–2950
   PubMed Web of Science ®Google Scholar
• Gandhi A K, Kang J, Naziruddin S, Parton A, Schafer P H, Stirling D I. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res 2006; 30: 849–858
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral L G, Wong K, Mueller J H, Moutouh-de P L, Jensen-Pergakes K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746–755
   PubMed Web of Science ®Google Scholar
• Moreira A L, Sampaio E P, Zmuidzinas A, Frindt P, Smith K A, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675–1680
   PubMed Web of Science ®Google Scholar
• Fujita J, Mestre J R, Zeldis J B, Subbaramaiah K, Dannenberg A J. Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2. Clin Cancer Res 2001; 7: 3349–3355
   PubMed Web of Science ®Google Scholar
• Dredge K, Horsfall R, Robinson S P, Zhang L H, Lu L, Tang Y, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69: 56–63
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Richardson P G, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525–4530
   PubMed Web of Science ®Google Scholar
• Schafer P H, Gandhi A K, Loveland M A, Chen R S, Man H W, Schnetkamp P P, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003; 305: 1222–1232
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005; 128: 192–203
   PubMed Web of Science ®Google Scholar
• Corral L G, Haslett P A, Muller G W, Chen R, Wong L M, Ocampo C J, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380–386
   PubMed Web of Science ®Google Scholar
• Wu L, Schafer P, Muller G, Stirling D, Bartlett J B. Lenalidomide strongly enhances natural killer (NK) cell mediated antibody-dependent cellular cytotoxicity (ADCC) of rituximab treated non-Hodgkin's lymphoma cell lines in vitro. Blood 2006; 108: 3714. (abstract)
   Google Scholar
• Kay N E. The angiogenic status of B-CLL B cells: role of the VEGF receptors. Leuk Res 2004; 28: 221–222
   PubMed Web of Science ®Google Scholar
• Mitsiades C S, Mitsiades N. CC-5013 (Celgene). Curr Opin Invest Drugs 2004; 5: 635–647
   PubMedGoogle Scholar
• Hernandez-Ilizaliturri F J, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003; 9: 5866–5873
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri F J, Reddy N, Holkova B, Ottman E, Czuczman M S. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11: 5984–5992
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri F J, Deeb G, Roth M, Vaughn M, Knight J, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36–45
   PubMed Web of Science ®Google Scholar
• Suvas S, Singh V, Sahdev S, Vohra H, Agrewala J N. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002; 277: 7766–7775
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller K C, DiMceli L, Padmanabhan S, Lawrence D, Bernstein Z P, et al. Results of phase II study of lenalidomide (L) (Revlimid) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2005; 106: 447
   PubMed Web of Science ®Google Scholar
• Witzig T E, Vose J M, Kaplan H P, Wolf J L, Pietronigro D, Takeshita K, et al. Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood 2006; 108: 2482. (abstract)
   Google Scholar
• Wiernik P H, Lossos I, Tuscano J, Justice G, Vose J, Pietronigro D, et al. Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood 2006; 108: 531. (abstract)
   Google Scholar